Authors
Latest:
Assay Shows Value for Patients With Low-Risk Prostate CancerAaron E. Katz, MD, discusses a genomic test for patients with low-risk prostate cancer.
Latest:
Tailored Treatment Approaches for Newly Diagnosed Follicular LymphomaTreatment advice for community oncologists and hematologists who treat follicular lymphoma based on therapeutic advances occurring rapidly in the field.
Latest:
Obstacles to Accessing Gynecologic Oncology Care With Insurance in the USAnna Jo Bodurtha Smith, MD, MPH, MSc, discusses her research on issues facing patients who need care for gynecologic cancers who have private insurance in the United States.
Latest:
CAR T-Cell Therapy Could Replace Auto Transplant in Multiple MyelomaThe depth and durability of responses seen with these CAR T-cell therapies in refractory myeloma is unprecedented and raises again the question of the role of up-front autologous stem cell transplant in the era of immune therapies, including CAR T-cell therapies.
Latest:
ctDNA Provides Guidance for Therapy Options in Epithelial Ovarian CancerctDNA offers clinicians the potential to determine whether to proceed with or discontinue PARP inhibitor maintenance therapy in patients with recurrent epithelial ovarian cancer.
Latest:
Accelerating Precision Medicine for Cancer PatientsTremendous strides in science have led to a wave of precision medicine-based approaches for patients that consider each patient’s underlying genetics and what makes each patient’s cancer unique.
Latest:
Improved MRD Detection Methods Aid in Posttransplant AMLAdaptation of improved methods of MRD detection are needed to better define this population at risk.
Latest:
Chronic GVHD: Prognoses and Future Directions in CareClosing out their discussion on graft-versus-host disease, participants reflect on patient prognoses and the future directions of care.
Latest:
Retrospective Study of Pola-BR for R/R LBCLAriel Perez, MD, discusses polatuzumab vedotin in combination with bendamustine and rituximab since garnering approval from the FDA and studies that evaluated the combination.
Latest:
Advice to Community Oncologists Treating SCLCGene G. Finley, MD, provides advice to community oncologists who are treating patients with small cell lung cancer.
Latest:
EGFR TKIs Excite Treatment Landscape of EGFR-Mutant Lung CancersJulia K. Rotow, MD, discusses the excitement of EGFR tyrosine kinase inhibitors for the treatment of patients with EGFR-mutant lung cancers.
Latest:
High Predictive Value Is Observed for Circulating Tumor Tissue in Oropharyngeal CancerResults from a study evaluating circulating tumor tissue–modified viral (TTMV)–human papillomavirus (HPV) DNA among patients treated for HPV-driven oropharyngeal squamous cell carcinoma is of interest.
Latest:
Navigating the Landscape of Immunotherapy ToxicitiesMatthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.
Latest:
Yocum Discusses Updated Data From the Beat AML Master TrialAshley Yocum, PhD, discusses the Beat AML trial of biomarker-based treatments in acute myeloid leukemia.
Latest:
Impact of the 2021 Lung Cancer Screening Guideline Update on Black Patients 1 Year LaterSelect racial groups have benefitted from important updates made to the USPSTF lung cancer screening guideline a year ago.
Latest:
Racial Disparities and Unmet Needs in Endometrial CancerRobert Holloway, MD, highlights the issue of racial disparity in endometrial cancer, and the critical unmet needs for patients.
Latest:
Next Steps in Cell TherapyPaul Lammers, MD, MSc, talks about the future of cell therapies and the applications of TAC-01 in solid tumors.
Latest:
The Future of Research in PEComasThe panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.
Latest:
Precision Medicine Implemented in the Community Oncology SettingTechnology plays a pivotal role in enhancing precision medicine within cancer care.
Latest:
Azacitadine Demonstrates Efficacy in a Phase 2 Trial of PTCLJia Ruan, MD, PhD, discusses the results of the multicenter phase 2 trial of oral azacitidine plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in patients with peripheral T-cell lymphoma.
Latest:
Haploidentical Transplant for Patients Without HLA-Matched DonorsAnne Wooford, MD, provides background on her presentation around allogeneic stem cell transplant for the 2022 Transplantation & Cellular Therapy Meetings.
Latest:
Using and Sequencing EGFR Exon 20-Targeted Therapies for NSCLCXiuning Le, MD, PhD, discusses counseling patients on the use of amivantamab-vmjw and mobocertinib and the sequencing of these drugs for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Latest:
Rationale, Data, and Future of Using Ide-Cel CAR T-Cell TherapyLarry D. Anderson, Jr, MD, PhD, discusses the rationale behind using chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma, data from the KarMMa trial, and other trials investigating this treatment.
Latest:
Perspectives on the Future on Myelofibrosis TreatmentStephen T. Oh, MD, PhD, concludes with thoughts on the future treatment landscape for myelofibrosis.
Latest:
Liquid Biopsies Become More Common for Gastric and GI CancersJoseph Kim, MD, discusses the utility of liquid biopsies in patients with gastric or gastrointestinal cancer at the 2020 GI Cancers Symposium held by the American Society of Clinical Oncology.
Latest:
Exploring the CLL14 Trial in Untreated CLL After 4 Years of Follow-upOthman Al-Sawaf, MD, discusses the use of venetoclax plus obinutuzumab in patients with untreated chronic lymphocytic leukemia on the CLL14 study.
Latest:
DFS vs OS Primary Endpoints in KEYNOTE 564Scott Tykodi, MD, PhD, discusses using DFS as a primary end point in trials, as well as the usage of biomarkers.
